equilife glp 1 GLP-1 Activator GLP-Activate | Hunger & Metabolism

[DOI] [Google Scholar] 47.Filippatos T.D., Panagiotopoulou T.V., Elisaf M.S

Accessed May 30, 2012

Approved injection sites for GLP-1 receptor agonists include the abdomen (generally avoiding the area around the navel), the front and outer aspects of the thighs, and the upper outer arm

Preclinical findings show remarkable consistency: GLP-1R agonists reduce voluntary substance intake, block drug-induced dopaminergic activation, inhibit conditioned reward learning, and attenuate relapse-like behaviors

The explanation for the discrepancy in the reduction of MACE in patients treated with SGLT2i in DECLARE-TIMI 58 suggests that the benefits of SGLT2i may be more pronounced in patients with a higher risk of cardiovascular disease